RNAGADE Trademark

Trademark Overview


On Wednesday, February 24, 2021, a trademark application was filed for RNAGADE with the United States Patent and Trademark Office. The USPTO has given the RNAGADE trademark a serial number of 90545040. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Wednesday, October 15, 2025. This trademark is owned by Renagade Therapeutics LLC. The RNAGADE trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations and substances, namely, RNA and DNA therapeutics for the treatment of infectious diseases, blood disorders, sepsis, alopecia, and cognitive disorders; pharmaceutical preparations, namely, RNA and DNA therapeutics for the prevention of osteoporosis; pharmaceutical preparations, namely, RNA and DNA therapeutics for the prevention of cancers, neurological disorders, cardiovascular disorders, inflammatory disorders, immunoregulatory disorders, metabolic disorders, infectious disorders, and reproductive disorders; pharmaceutical preparations, namely, RNA and DNA therapeutics for the treatment of immune system related diseases and disorders; pharmaceutical preparations for the treatment of infectious diseases; pharmaceutical preparations, namely, RNA and DNA therapeutics for the treatment of viral infections; pharmaceutical preparations, namely, RNA and DNA therapeutics for the treatment of cancers, neurological disorders, cardiovascular disorders, inflammatory di...
rnagade

General Information


Serial Number90545040
Word MarkRNAGADE
Filing DateWednesday, February 24, 2021
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateWednesday, October 15, 2025
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, March 14, 2023

Trademark Statements


Goods and ServicesPharmaceutical preparations and substances, namely, RNA and DNA therapeutics for the treatment of infectious diseases, blood disorders, sepsis, alopecia, and cognitive disorders; pharmaceutical preparations, namely, RNA and DNA therapeutics for the prevention of osteoporosis; pharmaceutical preparations, namely, RNA and DNA therapeutics for the prevention of cancers, neurological disorders, cardiovascular disorders, inflammatory disorders, immunoregulatory disorders, metabolic disorders, infectious disorders, and reproductive disorders; pharmaceutical preparations, namely, RNA and DNA therapeutics for the treatment of immune system related diseases and disorders; pharmaceutical preparations for the treatment of infectious diseases; pharmaceutical preparations, namely, RNA and DNA therapeutics for the treatment of viral infections; pharmaceutical preparations, namely, RNA and DNA therapeutics for the treatment of cancers, neurological disorders, cardiovascular disorders, inflammatory disorders, immunoregulatory disorders, metabolic disorders, infectious disorders, and reproductive disorders; pharmaceutical preparations, namely, RNA and DNA therapeutics for treating diabetes; pharmaceutical preparations, namely, RNA and DNA therapeutics for use in chemotherapy; pharmaceutical preparations, namely, RNA and DNA therapeutics for cancers, neurological disorders, cardiovascular disorders, inflammatory disorders, immunoregulatory disorders, metabolic disorders, infectious disorders, and reproductive disorders; pharmaceutical preparations, namely, antivirals; therapeutic pharmaceuticals, namely, RNA and DNA therapeutics for the treatment of cancers, neurological disorders, cardiovascular disorders, inflammatory disorders, immunoregulatory disorders, metabolic disorders, infectious disorders, and reproductive disorders; vaccine preparations, namely, RNA and DNA vaccine preparations; vaccines, namely, RNA and DNA vaccines; anti-epileptic pharmaceutical preparations; human vaccine preparations, namely, RNA and DNA vaccine preparations; medical preparations for the treatment of cancers, neurological disorders, cardiovascular disorders, inflammatory disorders, immunoregulatory disorders, metabolic disorders, infectious disorders, and reproductive disorders; medicinal preparations for the treatment of infectious diseases and for use in oncology; mixed biological preparations, namely, RNA and DNA therapeutics for the prevention and treatment of infectious diseases; pharmaceutical preparations, namely, RNA and DNA therapeutics for the prevention and treatment of ocular disorders or diseases, bacteria-based diseases or disorders, autoimmune diseases or disorders, kidney diseases or disorders, and diabetes; pharmaceutical preparations for the treatment of viral diseases; pharmaceutical products, namely, RNA and DNA therapeutics for the treatment of joint disease; pharmaceutical products, namely, RNA and DNA therapeutics for the treatment of viral and infectious diseases, for the treatment of cancer; therapeutic vaccines, namely, RNA and DNA therapeutics; all of the foregoing excluding medicinal dietary and nutritional supplements
Pseudo MarkRENAGADE RENEGADE

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateWednesday, May 26, 2021
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameRenagade Therapeutics LLC
Party Type20 - Owner at Publication
Legal Entity Type16 - Limited Liability Company
AddressWatertown, MA 02472

Party NameRenagade Therapeutics LLC
Party Type10 - Original Applicant
Legal Entity Type16 - Limited Liability Company
AddressCambridge, MA 02142

Trademark Events


Event DateEvent Description
Wednesday, September 15, 2021NON-FINAL ACTION WRITTEN
Saturday, February 27, 2021NEW APPLICATION ENTERED
Wednesday, May 26, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Wednesday, September 15, 2021ASSIGNED TO EXAMINER
Wednesday, September 15, 2021NON-FINAL ACTION E-MAILED
Wednesday, September 15, 2021NOTIFICATION OF NON-FINAL ACTION E-MAILED
Sunday, December 26, 2021TEAS RESPONSE TO OFFICE ACTION RECEIVED
Sunday, December 26, 2021CORRESPONDENCE RECEIVED IN LAW OFFICE
Monday, December 27, 2021TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, January 26, 2022FINAL REFUSAL WRITTEN
Wednesday, January 26, 2022FINAL REFUSAL E-MAILED
Wednesday, January 26, 2022NOTIFICATION OF FINAL REFUSAL EMAILED
Tuesday, July 26, 2022TEAS REQUEST FOR RECONSIDERATION RECEIVED
Tuesday, July 26, 2022EXPARTE APPEAL RECEIVED AT TTAB
Tuesday, July 26, 2022JURISDICTION RESTORED TO EXAMINING ATTORNEY
Tuesday, July 26, 2022EX PARTE APPEAL-INSTITUTED
Saturday, August 20, 2022ASSIGNED TO LIE
Saturday, August 20, 2022CORRESPONDENCE RECEIVED IN LAW OFFICE
Saturday, August 20, 2022TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, August 22, 2022ACTION CONTINUING FINAL - COMPLETED
Monday, August 22, 2022ACTION DENYING REQ FOR RECON E-MAILED
Wednesday, January 4, 2023TEAS REQUEST FOR RECONSIDERATION RECEIVED
Monday, August 22, 2022NOTIFICATION OF ACTION DENYING REQ FOR RECON E-MAILED
Wednesday, January 4, 2023JURISDICTION RESTORED TO EXAMINING ATTORNEY
Wednesday, January 4, 2023CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, January 4, 2023TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, February 7, 2023APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, February 22, 2023NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, March 14, 2023PUBLISHED FOR OPPOSITION
Tuesday, May 9, 2023NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Friday, October 20, 2023SOU TEAS EXTENSION RECEIVED
Friday, October 20, 2023SOU EXTENSION 1 FILED
Friday, October 20, 2023SOU EXTENSION 1 GRANTED
Tuesday, October 24, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, March 14, 2023OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Friday, March 17, 2023EXPARTE APPEAL TERMINATED
Tuesday, February 20, 2024ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Tuesday, February 20, 2024TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Tuesday, April 9, 2024SOU EXTENSION 2 GRANTED
Tuesday, April 9, 2024SOU EXTENSION 2 FILED
Tuesday, February 20, 2024TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Tuesday, February 20, 2024TEAS CHANGE OF CORRESPONDENCE RECEIVED
Tuesday, April 9, 2024SOU TEAS EXTENSION RECEIVED
Wednesday, April 10, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, October 4, 2024TEAS CHANGE OF OWNER ADDRESS RECEIVED
Friday, October 4, 2024APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Friday, October 4, 2024ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Friday, October 4, 2024TEAS CHANGE OF CORRESPONDENCE RECEIVED
Friday, October 4, 2024TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Thursday, October 24, 2024SOU TEAS EXTENSION RECEIVED
Wednesday, October 15, 2025ABANDONMENT - NO USE STATEMENT FILED
Wednesday, October 15, 2025ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Thursday, October 24, 2024SOU EXTENSION 3 GRANTED
Thursday, October 24, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, October 24, 2024SOU EXTENSION 3 FILED